Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Mylan Laboratories Inc. (NYSE:MYL)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 27Price hit new 52-week high ($36.00)
Location
1030 Century Building
130 Seventh Street
Pittsburgh, PA 15222
Phone: (412) 232-0100
Fax: (412) 232-0123
Email: investor_relations@mylan.com
Employees (last reported count): 2,220
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Products & Services
 ·Divisions
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 400 MidCap
Ownership
·Insider and 5%+ Owners: 11%
·Institutional: 62% (70% of float)
(529 institutions)
·Net Inst. Buying: 4.54M shares (+5.48%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Mylan Laboratories Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The Company conducts business through its generic (Generic Segment) and branded (Brand Segment) pharmaceutical operating segments. Mylan sells its products primarily to proprietary and ethical pharmaceutical wholesalers and distributors, drug store chains, drug manufacturers, institutions and governmental agencies within the United States. The Company's Generic Segment consists of two principal business units, Mylan Pharmaceuticals Inc. and UDL Laboratories Inc. Mylan's Brand Segment operates principally through its wholly owned subsidiary, Bertek Pharmaceuticals Inc.
More from Market Guide: Expanded Business Description

Financial Summary
Mylan Laboratories Inc. is engaged in the development, licensing, manufacturing, and marketing of generic and proprietary finished pharmaceutical and wound care products. For the three months ended 6/30/01, revenues rose 42% to $237.9 million. Net income totalled $50.6 million vs. a loss of $76.1 million. Revenues reflect increased generic segment sales and the introduction of Buspirone. Net income also reflects the absence of a $147 million litigation charge.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2001 Pay

Milan Puskar, 66
Chairman, CEO
$1.6M
C. Todd, 67
Pres, COO, Director
--  
Gary Sphar, 47
Interim CFO, VP-Fin.
--  
Dana Barnett, 60
Exec. VP
--  
James Mauzey, 52
Exec. VP; and Pres and CEO, Bertek Pharmaceuticals Inc.
--  
Dollar amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NYSE:MYLAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$20.15 
Recent Price$32.99 
52-Week High
on 27-Aug-2001
$36.00 
Beta0.64 
Daily Volume (3-month avg)1.17M
Daily Volume (10-day avg)1.02M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+21.6%
52-Week Change
relative to S&P500
+63.2%
Share-Related Items
Market Capitalization$4.13B
Shares Outstanding125.3M
Float111.5M
Dividends & Splits
Annual Dividend (indicated)$0.16 
Dividend Yield0.48%
Last Split: 3 for 2 on 16-Aug-1995
Per-Share Data
Book Value (mrq)$9.46 
Earnings (ttm)$1.30 
Earnings (mrq)$0.40 
Sales (ttm)$7.29 
Cash (mrq)$2.74 
Valuation Ratios
Price/Book (mrq)3.49 
Price/Earnings (ttm)25.34 
Price/Sales (ttm)4.53 
Income Statements
Sales (ttm)$917.4M
EBITDA (ttm)$255.0M
Income available to common (ttm)$163.9M
Profitability
Profit Margin (ttm)17.9%
Operating Margin (ttm)23.1%
Fiscal Year
Fiscal Year EndsMar 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)11.54%
Return on Equity (ttm)14.88%
Financial Strength
Current Ratio (mrq)3.08 
Debt/Equity (mrq)0.02 
Total Cash (mrq)$342.8M
Short Interest
As of 8-Aug-2001
Shares Short3.66M
Percent of Float3.3%
Shares Short
(Prior Month)
3.33M
Short Ratio3.78 
Daily Volume967.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.